AVADEL PHARMACEUTICALS PLC — Director's Dealing 2022

Feb 16, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2022-02-14

Reporting Person: Williamson Douglas J (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-14	Stock Option (Right to Buy)	$6.6	A	275000	Acquired	2032-02-14	ADSs (275000)	Direct

Footnotes

F1: Options become exercisable as to 68,750 ADSs on each of the first four anniversaries after the 2/14/2022 grant date.

F2: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.